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6–42 g/ml (days 4–6), in synchrony with the T-cell nadirs, and
became undetectable by day 13. Antibodies to rabbit ATG ap-
peared after 6–7 days, and their titers increased as ATG was
cleared from the circulation. We then evaluated the immunosup-
pressive effects of ATG using allogeneic skin grafts. Median skin
graft survival in 5 dogs given ATG was 14 days, compared to 8 days
among 28 controls (p  0.0003). Based on these observations, an
HCT protocol was designed; 5 dogs were given ATG (3.5–5
mg/kg) between days –12 and –7 to target a 90–95% depletion of
circulating T cells. ATG levels were undetectable by day 0, ex-
cluding possible effects on donor T cells. On day 0, dogs were
given 1 Gy TBI and marrow from dog leukocyte antigen-identical
donors. Median cell doses infused (millions/kg) were: total nucle-
ated cells (TNC)  263; CD34  6.6 and CD3  18. Posttrans-
plant immunosuppression was MMF/CSP for 4 and 5 weeks,
respectively. All recipients showed initial donor chimerism, with
maximal values ranging from 10–75% (median 25%) for granulo-
cytes and 5–40% (median 25%) for mononuclear cells. Four dogs
rejected their grafts after a median of 9.5 weeks (range 8–18
weeks), without cytopenias, and they reverted to autologous hema-
topoiesis. The 5th dog has remained a long-term mixed chimera
(36 weeks). The median times to rejection were 11 weeks (pro-
jected) in the study group and 10 weeks in the control group, not
given ATG (p  0.20, log-rank test). Analysis of the impact of cell
doses suggested that TNC had the highest Spearman correlation
coefﬁcient with the duration of donor chimerism, 0.82 (p  0.09).
We conclude that ATG reliably depleted circulating T cells by
90–95% and lymph node T cells by approximately 50%. Even so,
administering ATG before an otherwise inadequate conditioning
dose of 1 Gy TBI failed to lead to uniform stable hematopoietic
engraftment.
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THE IMPACT OF PRE-TRANSPLANT ANEMIA ON LONG-TERM SURVIVAL
FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION
Xenocostas, A.1, Wong, C.J.2, Lazongas, C.3, Sutton, D.M.3, Daly, A.3,
Kiss, T.L.4, Lipton, J.H.3, Messner, H.A.3 1. Department of Hema-
tology, London Health Sciences Centre and the University of West-
ern Ontario, London, ON, Canada; 2. Robarts Clinical Trials, Robarts
Research Institute and the University of Western Ontario, London,
ON, Canada; 3. Department of Medical Oncology and Hematology,
Princess Margaret Hospital/University Health Network and the Uni-
versity of Toronto, Toronto, ON, Canada; 4. Department of Hemato-
Oncology, Sacre Coeur Hospital/University of Montreal, Montreal, QC,
Canada.
Background: Anemia is a common ﬁnding in patients with
malignancies and is associated with reduced survival times. The
impact of anemia on survival during allogeneic bone marrow trans-
plantation (alloBMT) was not known. Recently, we identiﬁed that
low pre-transplant hemoglobin (PT-Hb) levels were associated
with increased mortality during the ﬁrst 6 months after BMT.
However, the impact of the PT-Hb on long-term survival was not
known. Study Design and Methods: Data from 519 consecutive
patients receiving transplants between January 1995 and March
2000 were retrospectively reviewed and survival was evaluated with
regard to risk factors, including the PT-Hb until June 2002. Sur-
vival was calculated using Kaplan-Meier limit methods. Risk factor
subgroups were compared with the log rank test. The PT-Hb
levels were determined within 2 weeks of conditioning chemora-
diotherapy. Results: PT-Hb levels correlated inversely with sur-
vival. The percentile 5-year survival of patients with PT-Hb levels
of 100, 101-110, 111-120, 121-130 and 130 g/L were 35, 29,
46, 62, and 57, respectively, not taking into account any other
known transplant-related risk factors. Patients with PT-Hb levels
of 110 g/L compared to 110 g/L had 5-year survival rates of
33% versus 56% (p  0.001). The effect of the PT-Hb on survival
was sustained in subgroups of patients presenting with low or
high-risk disease at the time of BMT. The overall 5-year survival
rate was 46%. By univariate analyses, the PT-Hb, the use of
unrelated donors, BMT in patients with more advanced disease
and major ABOmismatch between donor and recipient were found
to be signiﬁcant risk factors for mortality. In a multivariate model,
a low PT-Hb level was found to be an independent risk factor (p
0.001; hazard ratio, 1.19 per 10 g/L decrease; 95% CI, 1.10–1.28).
Conclusion: Pre-transplant anemia is an independent risk factor
for increased long-term mortality during alloBMT. It remains to
be determined whether decreased survival is the result of direct
effects from anemia or, alternatively, a low PT-Hb level may
represent surrogate marker for other adverse transplant-related
parameters.
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LOW DOSE TOTAL BODY IRRADIATION, FLUDARABINE AND ANTI-
THYMOCYTE GLOBULIN CONDITIONING FOR MULTIPLE MYELOMA
(MM)
Grosskreutz, C.L., Scigliano, E., Fruchtman, S.M., Luis, I.M. Mount
Sinai Medical Center, New York, NY.
Seven patients with multiple myeloma underwent non-myeloab-
lative stem cell transplant (NST) with ATG 15 mg/kg/day days -4
to -1, TBI 200 cGy on a single fraction on day -5, and ﬂudarabine
30 mg/m2/day on days -4 to -2. Immunosuppressive therapy was
oral mycophenolate mofetil 15 mg/kg every 12 hours and cyclo-
sporine 6 mg/kg every 12 hours started on day -5. Grafts were
unmanipulated PBPC mobilized with ﬁlgrastim 10 ug/kg/day and
collected on day 5. The median age of the recipients was 54 years
(range, 38-60). Three patients had 2 prior autologous stem cell
transplant (ASCT) and 3 had one prior ASCT. Three patients had
refractory MM, 2 had PR to prior therapies, 1 had relapsed disease
and 1 was in CR at the time of transplant. Three patients had
cytogenetics abnormalities: 2 had del 13q14 and 1 del q20. Three
patients had monoclonal IgG kappa, 2 IgA kappa and 2 kappa light
chains. Six patients received a full match related graft and one had
full match (10/10) unrelated donor graft. Five of seven patients
were evaluable for chimerism. Three had 90% and 2 had 80%
donor chimerism by day 30. Four patients are alive two of them in
CR with a follow up time of 307 and 951 days. One of them had
refractory disease at the time of NST. One patient is 61 days post
transplant in PR showing continued response. One patient is 93
days post transplant and has a mixed response evidenced by com-
plete disappearance of plasma cells in bone marrow and normal
IPEP but a new plasmacytoma in the skull. Three patients died; 2
from infectious complications on days 40 and 57 and one at day 19
with CNS toxicity presumed secondary to ﬂudarabine. One patient
developed pulmonary aspergillosis and CMV disease, both re-
solved with appropriate therapy. Three patients developed acute
GvHD, 2 had cutaneous grade I and 1 grade III of liver, gut and
skin (unrelated donor graft). All 3 are alive with resolution of the
GvHD.The addition of ATG to low dose TBI, ﬂudarabine NST
conditioning results in high rate of donor chimerism, preserved
graft versus myeloma effect and might help decrease the incidence
or severity of GvHD by in vivo T-cell depletion. These results
provide an alternative to reduced intensity conditioning with mel-
phalan for allogeneic transplantation in MM.
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IMPROVING DOSING PRECISION IN BUSULFAN (BU)-BASED PREPAR-
ATIVE REGIMENS FOR HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION (HSCT) USING PARMACOKINETICS DIRECTED THERAPY (PKDT)
Nance, A.G., Teresi, W.M., Vaughan, W.P., McKay, J.T., Salzman,
D.E. University of Alabama Hospital, Birmingham, AL.
Variation in po Bu absorption and metabolism in patients (Pts)
undergoing HSCT contributes to increased relapse rate and excess
toxicity. PK studies with ivBu conﬁrm minimal variation in area
under the concentrationXtime curve (AUC) in serial doses given to
individual Pts and reduction in variation in time to max dose, but
little decrease in interpatient variation. These studies suggest that
dosing to achieve a precise drug exposure based upon test dose PK
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can be achieved. Attempts to accomplish this must consider drug
interactions with itraconazole and acetaminophen, both of which
increase Bu level by competing for glutathione reductase depen-
dent metabolism, or dilantin and rifampicin, which decrease Bu
level due to metabolic pathway activation. We developed a limited
sampling strategy that simpliﬁes Bu PK when the iv drug is used.
We have begun studies to determine the ability of test dose PK to
predict later Bu levels. Pts are given the ﬁrst of 16 2-hr infusions of
ivBu “test dose” 48 hr prior to the beginning of the remaining 15
Q6h doses adjusted to achieve a target AUC on the basis of 1st dose
PK. PK study is performed using a 5-sample limited sampling
strategy and a single compartment, ﬁrst order elimination model in
WinNonlin. Pts receive lorazepam for seizure prophylaxis to avoid
any dilantin effect. 13 Pts received this Bu-based HSCT prepara-
tive regimen between April and June 2003, 5 required no dose
adjustment for dose 2, 5 required an increase and 3 required a
decrease. Despite adjustment we found greater than 10% variation
from predicted AUC for dose 2 in 5 Pts. The largest (30% higher
than predicted) occurred in a Pt who received voriconazole be-
tween dose 1 and dose 2. The second largest (23% lower that
predicted) occurred in a Pt who was taking an acetaminophen prior
to dose 1. The 3rd and 4th highest (21% and 14% higher than
predicted) occurred in Pts with a rise in serum bilirubin level
between doses. Thus 8/9 Pts without a presumptive cause for
instability in drug metabolism, including previously undocumented
concomitant voriconazole, had dose 2 AUC within 10% of pre-
dicted using dose 1 PKDT. Dosing precision with ivBu is achiev-
able, but precautions to assure absence of drug interaction or
changing hepatic function are necessary. Dosing precision with
ivBu will improve safety and effectiveness of HSCT using Bu-
based preparative regimens and greatly facilitate research into
modiﬁed preparative regimens for allogeneic HSCT.
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SUCCESSFUL TREATMENT OF HEPATIC VENO-OCCLUSIVE DIS-
EASE(VOD) AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION
BY EARLY ADMINISTRATION OF A SHORT COURSE OF METHYLPRED-
NISOLONE
AlBeihany, A.M., AlOmar, H.A., Sahovic, E., Chaudhri, N.A., AlMo-
hareb, F.I., AlShanqeeti, A., AlSharif, F., AlZahrani, H., Seth, P.,
AlQurashi, F., Zaidi, S., Morshed, M., AlHijazi, A., Gyger, M., Aljurf,
M.D. Oncology Dept, King Faisal Specialist Hospital& Research Center,
Riyadh, Saudi Arabia.
Hepatic Veno-Occlusive Disease (VOD) is a well-recognized life
threatening complication of hemopoietic stem cell transplantation.
Cytokine release from tissue injury resulting from high doses of
chemo/radiotherapy plays a major role in pathogenesis of VOD.
We postulate that corticosteroids might ameliorate the severity of
disease and improve the outcome. Between January 1997 and
December 2002, 410 consecutive adult patients received allogeneic
stem cell transplant at our institution. Using Seattle’s criteria, 49
patients were diagnosed to have VOD (11%). Treatment consisted
of methylprednisolone (MP) 0.5mg/kg i.v. q.12.h for seven days,
and standard supportive therapy of ﬂuid/salt restriction and diuret-
ics. Median age was 29 years (15.4-55.7). Twenty-four patients
were male and 25 were female. Primary diagnoses were AML (13),
ALL (12), CML (17), MDS (6), NHL (1). Bone marrow was the
source of stem cells in 43 (87.8%), and peripheral blood in 6
(12.2%) patients. All donors were HLA-matched siblings except
for a case of one antigen mismatch. Thirty-six (73.5%) patients
received conditioning with Bu/Cy and 13 (26.5%) TBI containing
regimen. GVHD prophylaxis was standard CSA with short course
of methotrexate. All patients received Fluconazole prophylaxis and
G-CSF was used in 31 (63%) patients. One patient was positive for
Hepatitis B surface antigen and one had hepatitis C virus antibod-
ies. Median bilirubin was 169 m m/L (38-1169). Weight gain was
present in 47 (90%) patients and right upper quadrant tenderness
in 43 (87%) patients. Thirty-two (65%) of the patients had other
organ failure(s) including multi-organ failure (MOF) in 15, renal in
9, respiratory in 6, cardiac failure, and CNS toxicity in 1 patient.
Response was deﬁned using Bearman’s criteria (Blood 1997; 89:
1501-1506) as reduction by 50% of serum bilirubin within 10 days
of initiation of high dose MP. Results: Twenty (40%) patients
responded to treatment. By day100, 17 (35%) patients were alive
and without evidence of VOD, all were among responders to
therapy. There were no serious adverse effects of treatment.
Causes of death were: VOD in 11, relapse in 10, MOF in 7,
pneumonitis in 1, bleeding in 1, infection in 1, and one sudden
death at home. We conclude that MP is safe and effective treat-
ment of VOD. Our response and survival data compare favorably
with other available reported alternative therapies for VOD; how-
ever, these results need to be conﬁrmed by a randomized con-
trolled trial.
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RISK ASSESSMENT AND OUTCOME OF CHRONIC GRAFT-VERSUS-HOST
DISEASE AFTER ALLOGENEIC PERIPHERAL BLOOD PROGENITOR CELL
TRANSPLANTATION IN PEDIATRIC PATIENTS
Diaz, M.A.1, Gonzalez Vicent, M.1, Gonzalez Valentin, M.E.2, Ver-
deguer, A.3, de la Rubia, J.3, Bargay, J.4, de Arriba, F.5, Diez, J.L.6,
Caballero, D.7, Madero, L.1, Brunet, S.8 1. Hospital Infantil “Nin˜o
Jesus,” Madrid, Madrid, Spain; 2. Hospital “Carlos Haya,” Malaga,
Malaga, Spain; 3. Hospital “La Fe,” Valencia, Valencia, Spain; 4.
Hospital Son Dureta, Mallorca, Mallorca, Spain; 5. Hospital Gral,
Murcia, Murcia, Spain; 6. Hospital “Gregorio Maran˜on,” Madrid,
Madrid, Spain; 7. Hospital Clinico Universitario, Salamanca,
Salamanca, Spain; 8. Hospital San Pau, Barcelona, Barcelona, Spain.
We evaluated the incidence, risk factors for cGvHD and clinical
outcome in 80 pediatric patients (36 male and 44 female) (median
age 13 years; range 1 to 18) who underwent allogeneic PBPC
transplantation. All patients were grafted from an HLA-identical
sibling after myeloablative conditioning (TBI-based 52; non-TBI
28). GvHD prophylaxis used were CsA short methotrexate in 52
and CsA predinosone in 28. The median number of CD34 cells
infused was 5.8 x 106/Kg (range; 1.4-32.8). The median follow-up
was 24 months (range; 3-94). Twenty-eight patients had cGvHD.
The cumulative incidence of cGvHD at 24 months was 54.210%.
Factors that were found signiﬁcant on univariate analysis were
diagnosis (p  0.03) and GvHD prophylaxis used (p  0.04). A
trend to higher risk of cGvHD was found with higher numbers of
CD34 and CD3 cells infused. On multivariate analysis, only
the GvHD prophylaxis used other than CsA plus short MTX was
associated with a signiﬁcant risk of cGvHD (HR 3.94; 95% CI:
1.41-10.91, p  0.009). The cumulative incidence of cGvHD for
patients receiving MTX was 40.912% whereas for patients who
did not received MTX was 76.518% (HR 2.39; 95% CI: 1.05-
7.49; p  0.03).
The probability of relapse was 366% for all patients, being of
12.58% for patients with cGvHD and 47.98% for patients
without cGvHD. There was no difference in the probability of
TRM between patients with or witout cGvHD (307% vs
146%; p  0.1). The probabilty of DFS was better for patients
with cGvHD (69.910% vs 37.97%; HR 3.59, 95% CI: 1.47-
5.56; p 0.001). In conclusion, our data suggest that the incidence
of cGvHD after allogeneic PBPC transplantation in children is
higher than reported using bone marrow and that the usually
considered risk factors for cGvHD in bone marrow were not found
associated with an increased risk of cGvHD being the GvHD
prophylaxis used the most relevant predictor of cGvHD. Patients
with cGvHD had a lower risk of relapse and a better survival.
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INHALED CYCLOSPORINE: A SAFE AND EFFECTIVE AEROSOL THERAPY
FOR CHRONIC GRAFT VERSUS HOST DISEASE INVOLVING LUNG
Anderson, P.M., Rodriguez, V., Erlandson, L., Heying, J., Brenna, J.,
Wylam, M.E. Mayo Clinic, Rochester, MN.
Bronchiolitis obliterans organizing pneumonia (BOOP) and
bronchiolitis obliterans (BO) are restrictive, inﬂammatory pro-
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